--- title: "Medical Countermeasure" description: "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member." url: "https://cbrneworld.com/component/tags/tag/medical-countermeasure" date: "2026-07-30T21:43:38+00:00" language: "en-GB" --- Written on 14 January 2025. ## [Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax](https://cbrneworld.com/news/emergent-biosolutions-announces-exercise-of-20-million-option-to-supply-u-s-department-of-defense-with-biothrax) Emergent BioSolutions Inc. (NYSE: EBS) today announced the exercise of contract option and modification valued at approximately $20 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense (DoD). The first delivery, which was valued at approximately $7 ... Written on 10 January 2025. ## [First potential antidote for hydrogen sulfide poisoning created](https://cbrneworld.com/news/news-first-potential-antidote-for-hydrogen-sulfide-poisoning-created) Originally published by Chemistry World Researchers have developed a novel antidote to treat hydrogen sulfide poisoning. It is hoped that this innovation will save the lives of workers and rescue personnel. ... [![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2FNews-Images%2FCrossject.jpg%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=588cc944)](https://cbrneworld.com/news/crossjects-zeneo-auto-injectors-usability-further-demonstrated-in-extreme-hazmat-conditions) Written on 18 November 2024. ## [Crossject’s ZENEO Auto-Injector's usability further demonstrated in extreme HAZMAT conditions](https://cbrneworld.com/news/crossjects-zeneo-auto-injectors-usability-further-demonstrated-in-extreme-hazmat-conditions) Crossject, a specialty pharma company developing the award-winning needle-free ZENEO® auto-injector to deliver life-saving medicines in emergency situations,has successfully completed a human factors study under extreme stress conditions. The test, designed ... [![](https://cbrneworld.com/templates/yootheme/cache/08/Kaleo-Color-RGB-Digital-0862fa44.jpeg)](https://cbrneworld.com/news/u-s-department-of-health-and-human-services-awards-kaleo-with-contract-to-develop-next-generation-organophosphate-nerve-agent-poisoning-countermeasure) Written on 17 April 2024. ## [U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure](https://cbrneworld.com/news/u-s-department-of-health-and-human-services-awards-kaleo-with-contract-to-develop-next-generation-organophosphate-nerve-agent-poisoning-countermeasure) Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to ... [![](https://cbrneworld.com/images/News-Images/barda_logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/barda-preclinical-testing-services-for-botulinum-neurotoxin-therapeutics) Written on 12 February 2024. ## [BARDA Preclinical Testing Services for Botulinum Neurotoxin Therapeutics](https://cbrneworld.com/news/barda-preclinical-testing-services-for-botulinum-neurotoxin-therapeutics) One of the challenges faced by many early academic and small business research partners is the cost associated with demonstrating a therapeutic candidate’s effectiveness in relevant efficacy models. BARDA invites researchers to submit proposals to the Botulinum Neurotoxin (BoNT) Candidate ... [![](https://cbrneworld.com/images/News-Images/3M.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/3m-receives-34-2-million-award-to-improve-treatment-of-traumatic-wounds-from-point-of-injury-to-hospital) Written on 15 January 2024. ## [3M receives $34.2 million award to improve treatment of traumatic wounds from point-of-injury to hospital](https://cbrneworld.com/news/3m-receives-34-2-million-award-to-improve-treatment-of-traumatic-wounds-from-point-of-injury-to-hospital) 3M Health Care's [Medical Solutions Division](https://c212.net/c/link/?t=0&l=en&o=4063363-1&h=3477872547&u=https%3A%2F%2Fwww.3m.com%2F3M%2Fen_US%2Fmedical-us%2F&a=Medical+Solutions+Division), the world ... [![](https://cbrneworld.com/images/News-Images/barda_logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/barda-awards-117-million-for-first-clinical-trial-for-new-ards-treatments) Written on 10 January 2024. ## [BARDA Awards $117 Million for First Clinical Trial for New ARDS Treatments](https://cbrneworld.com/news/barda-awards-117-million-for-first-clinical-trial-for-new-ards-treatments) The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR), announced a $117 million contract to simultaneously evaluate three novel therapeutics to treat hospitalized adult patients with acute respiratory ... [![](https://cbrneworld.com/images/News-Images/barda_logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/barda-selects-management-firm-for-new-biopharmaceutical-manufacturing-preparedness-consortium) Written on 10 January 2024. ## [BARDA selects management firm for new Biopharmaceutical Manufacturing Preparedness Consortium](https://cbrneworld.com/news/barda-selects-management-firm-for-new-biopharmaceutical-manufacturing-preparedness-consortium) BARDA has selected Advanced Technology International (ATI) as the new Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium) management firm. The BioMaP-Consortium is a new 10-year program to improve domestic capabilities to manufacture and deliver vital medical ... [![](https://cbrneworld.com/images/News-Images/DMTC-logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/pushing-back-against-viruses-with-pandemic-potential) Written on 21 August 2023. ## [Pushing back against viruses with pandemic potential](https://cbrneworld.com/news/pushing-back-against-viruses-with-pandemic-potential) .Health Security Systems Australia (HSSA) is working with experts at the University of Melbourne at the Peter Doherty Institute for Infection and Immunity (Doherty Institute), The University of Queensland’s National Biologics Facility, and industry partner Biointelect Pty Ltd to develop a novel ... [![](https://cbrneworld.com/images/events/sponsor_logos/EMERGENT_Logo_New_2021.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/emergent-biosolutions-receives-u-s-fda-approval-of-cyfendus-a-two-dose-anthrax-vaccine-for-post-exposure-prophylaxis-use) Written on 21 July 2023. ## [Emergent BioSolutions receives U.S. FDA approval of CYFENDUS. a two-dose anthrax vaccine for post-exposure prophylaxis use](https://cbrneworld.com/news/emergent-biosolutions-receives-u-s-fda-approval-of-cyfendus-a-two-dose-anthrax-vaccine-for-post-exposure-prophylaxis-use) Emergent BioSolutions Inc. announced on July 20, 2023 that the U.S. Food and Drug Administration (FDA) has approved CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure ... [![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2FNews-Images%2FKaleo-MCM-Gear_RADA.jpg%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=0d2de393)](https://cbrneworld.com/news/u-s-department-of-defense-selects-kaleo-to-develop-next-generation-nerve-agent-countermeasure) Written on 18 July 2023. ## [U.S. DOD Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure](https://cbrneworld.com/news/u-s-department-of-defense-selects-kaleo-to-develop-next-generation-nerve-agent-countermeasure) Kaléo selected to develop Reconstitution Auto-Injector Device [![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2FNews-Images%2FMedicinova.png%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=259f24d6)](https://cbrneworld.com/news/medicinova-announces-additional-extension-of-barda-contract-to-develop-mn-166-ibudilast-as-a-medical-countermeasure-against-chlorine-gas-induced-lung-injury) Written on 15 March 2023. ## [MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury](https://cbrneworld.com/news/medicinova-announces-additional-extension-of-barda-contract-to-develop-mn-166-ibudilast-as-a-medical-countermeasure-against-chlorine-gas-induced-lung-injury) MediciNova, Inc.,has announced a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA), a part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services, to ... [![](https://cbrneworld.com/images/events/sponsor_logos/EMERGENT_Logo_New_2021.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/emergent-biosolutions-receives-department-of-defense-award-to-evaluate-chikungunya-vaccine-candidate-in-post-approval-field-efficacy-study-using-model-guided-approach) Written on 18 November 2022. ## [Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach](https://cbrneworld.com/news/emergent-biosolutions-receives-department-of-defense-award-to-evaluate-chikungunya-vaccine-candidate-in-post-approval-field-efficacy-study-using-model-guided-approach) orginally published by Emergent BioSolutions Inc. (NYSE:EBS) announced today a research award by the U.S. Department of Defense (DoD) Congressionally Directed Medical Research Programs (CDMRP) to evaluate ... [![](https://cbrneworld.com/images/News-Images/Rafa-Logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/rafa-receives-fda-approval-for-life-saving-midazolam-autoinjector) Written on 30 August 2022. ## [Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector](https://cbrneworld.com/news/rafa-receives-fda-approval-for-life-saving-midazolam-autoinjector) [Rafa Laboratories LTD.](https://www.rafa.co.il/en) ("Rafa") is pleased to announce the U.S. Food and Drug Administration has approved its "first in market" 10 mg midazolam autoinjector for the treatment of status epilepticus in adults. The ... Written on 26 July 2022. ## [Fastox to present its long-lasting botulinum toxin LAST technology at the TOXINS 2022 6th International Conference.](https://cbrneworld.com/news/fastox-to-present-its-long-lasting-botulinum-toxin-last-technology-at-the-toxins-2022-6th-international-conference) Swiss biotech Fastox Pharma will present for the first time its groundbreaking long-lasting botulinum toxin LAST technology at the leading conference on neurotoxins from July 27thto July 30th in New Orleans, USA. Fastox has discovered that combining botulinum toxin type A (BoNT/A) with ... [![](https://cbrneworld.com/images/events/sponsor_logos/EMERGENT_Logo_New_2021.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/chimerix-announces-sale-of-tembexa-to-emergent-biosolutions) Written on 23 May 2022. ## [Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions](https://cbrneworld.com/news/chimerix-announces-sale-of-tembexa-to-emergent-biosolutions) Chimerix, a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announces it has entered into a definitive agreement with Emergent BioSolutions Inc. (Emergent) to acquire its exclusive ... [![](https://cbrneworld.com/images/News-Images/SIGA-Technologies-Inc.-logo.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/siga-receives-fda-approval-for-iv-formulation-of-tpoxx) Written on 23 May 2022. ## [SIGA Receives FDA approval for IV Formulation of TPOXX](https://cbrneworld.com/news/siga-receives-fda-approval-for-iv-formulation-of-tpoxx) SIGA Technologies, Inc. (SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the U.S. Food and Drug Administration (FDA) approved the intravenous (IV) formulation of TPOXX for the treatment of smallpox. The IV formulation is an important ... [![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2FNews-Images%2FPlague.jpg%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=5fd59b70)](https://cbrneworld.com/news/dod-awards-dynavax-22-million-for-plague-vaccine-clinical-trial) Written on 10 November 2021. ## [DOD Awards Dynavax $22 Million for Plague Vaccine Clinical Trial](https://cbrneworld.com/news/dod-awards-dynavax-22-million-for-plague-vaccine-clinical-trial) The U.S. Department of Defense (DOD) awarded Dynavax Technologies Corporation with an agreement worth approximately $22 million over two and a half years, to execute a clinical trial combining the DOD’s recombinant plague (rF1V) vaccine with its own CpG 1018® adjuvant. Under the agreement, ... [![](https://cbrneworld.com/images/News-Images/medicinova-inc-logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/medicinova-announces-partnership-with-barda-to-develop-mn-166-ibudilast-as-a-medical-countermeasure-against-chlorine-gas-induced-lung-injury) Written on 11 March 2021. ## [MediciNova Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury](https://cbrneworld.com/news/medicinova-announces-partnership-with-barda-to-develop-mn-166-ibudilast-as-a-medical-countermeasure-against-chlorine-gas-induced-lung-injury) MediciNova, Inc., a biopharmaceutical company, today announced it has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and ... [![](https://cbrneworld.com/templates/yootheme/cache/9b/Monkeypox-9bcd143c.jpeg)](https://cbrneworld.com/news/health-canada-extends-approval-of-imvamune-to-immunization-against-monkeypox-and-orthopox-viruses) Written on 17 November 2020. ## [Health Canada Extends Approval of IMVAMUNE to Immunization Against Monkeypox and Orthopox Viruses](https://cbrneworld.com/news/health-canada-extends-approval-of-imvamune-to-immunization-against-monkeypox-and-orthopox-viruses) Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox and related orthopoxvirus infections and disease in ... [![](https://cbrneworld.com/images/News-Images/barda_logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/?view=article&id=1802:barda-partners-with-invirsa-to-develop-a-treatment-for-ocular-conditions-associated-with-dna-damage-including-sulfur-mustard-injury&catid=2) Written on 12 November 2020. ## [BARDA partners with Invirsa to develop a treatment for ocular conditions associated with DNA damage, including sulfur mustard injury](https://cbrneworld.com/?view=article&id=1802:barda-partners-with-invirsa-to-develop-a-treatment-for-ocular-conditions-associated-with-dna-damage-including-sulfur-mustard-injury&catid=2) BARDA is partnering with[ Invirsa](http://invirsa.com/)to develop the company’s investigational product INV-102 to treat ocular conditions associated with DNA damage to include sulfur mustard injury. By funding this advanced research and development ... [![](https://cbrneworld.com/component/ajax/?p=image&src=%7B%22file%22%3A%22images%2FNews-Images%2FEbola.jpg%22%2C%22thumbnail%22%3A%22%2C%22%7D&hash=88e0fa74)](https://cbrneworld.com/news/fda-approves-first-treatment-for-ebola) Written on 16 October 2020. ## [FDA approves first treatment for Ebola](https://cbrneworld.com/news/fda-approves-first-treatment-for-ebola) On October 14 the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved treatment for *Zaire ebolavirus* (Ebola virus) infection in adult and pediatric ... [![](https://cbrneworld.com/images/News-Images/SRI-Logo.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/sri-international-awarded-100m-contract-by-niaid-for-radiation-nuclear-medical-countermeasures) Written on 06 August 2020. ## [SRI International Awarded $100M Contract by NIAID for Radiation/Nuclear Medical Countermeasures](https://cbrneworld.com/news/sri-international-awarded-100m-contract-by-niaid-for-radiation-nuclear-medical-countermeasures) SRI International has been awarded a contract of up to from the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to support the research and development of radiation/nuclear medical countermeasures (MCMs). Under the contract, SRI ... [![](https://cbrneworld.com/images/News-Images/PharmaJetLogo-adjusted.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/pharmajet-receives-award-to-support-next-generation-needle-free-delivery-devices) Written on 18 March 2020. ## [PharmaJet Receives Award to Support Next-Generation Needle-free Delivery Devices](https://cbrneworld.com/news/pharmajet-receives-award-to-support-next-generation-needle-free-delivery-devices) [PharmaJet](https://pharmajet.com/), the maker of innovative, needle-free injection technology, announced that it received a $9.6 million dollar contract award from the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency ... [![](https://cbrneworld.com/images/News-Images/inovio-logo-color.png#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/cepi-grants-9m-to-inovio-to-develop-coronavirus-vaccine) Written on 24 January 2020. ## [CEPI grants $9M to Inovio to develop coronavirus vaccine](https://cbrneworld.com/news/cepi-grants-9m-to-inovio-to-develop-coronavirus-vaccine) Inovio Pharmaceuticals, USA has announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's ... [![](https://cbrneworld.com/templates/yootheme/cache/ca/UMN__Windgap-ca1264e1.jpeg)](https://cbrneworld.com/news/cyanide-autoinjector-development) Written on 15 January 2020. ## [Cyanide Autoinjector Development](https://cbrneworld.com/news/cyanide-autoinjector-development) The University of Minnesota Twin Cities and Windgap Medical have received a $3.2 million grant from the National Institutes of Health (NIH) to develop a new device to quickly administer a recently developed antidote for cyanide poisoning. Under the grant, researchers from the ... [![](https://cbrneworld.com/images/News-Images/barda_logo.jpg#thumbnail=%2C&srcset=1)](https://cbrneworld.com/news/barda-procures-nexobrid-for-emergency-response) Written on 08 January 2020. ## [BARDA Procures NexoBrid for Emergency Response](https://cbrneworld.com/news/barda-procures-nexobrid-for-emergency-response) MediWound Ltd. and its U.S. commercial partner Vericel Corporation have announced that BARDA has begun procuring [NexoBrid](https://www.nexobrid.com/) for emergency stockpile as part of the HHS mission to build national preparedness for public ... ## Schema ```json { "@context": "https://schema.org", "@type": "Organization", "@id": "https://cbrneworld.com/component/tags/tag/medical-countermeasure#organization", "name": "CBRNe World Magazine", "description": "CBRNe World provides those tasked with defending against CBRN and IED threats with the essential practical, scientific and political information. Access the current and previous issues of the magazine by registering as a member.", "email": "enquiries@cbrneworld.net", "url": "https://cbrneworld.com", "telephone": "+447504613126", "logo": "https://cbrneworld.com/images/default/Asset%201.png", "image": "https://cbrneworld.com/images/default/Asset%201.png", "address": { "@type": "PostalAddress", "streetAddress": "3a Upper High Street", "addressCountry": "GB", "addressLocality": "Winchester", "addressRegion": "Hampshire", "postalCode": "SO23 8UT" }, "sameAs": [ "https://www.facebook.com/cbrneworld", "https://twitter.com/cbrneworld", "https://www.linkedin.com/company/cbrne-world", "https://www.youtube.com/@TheRealCBRNeWorld" ] } ``` ```json { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Medical Countermeasure", "item": "https://cbrneworld.com/component/tags/tag/medical-countermeasure" } ] } ```